公开(公告)号：US20210361449A1

公开(公告)日：2021-11-25

申请号：US17322829

申请日：2021-05-17

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua SUN ,  Christophe BUREAU ,  Wenbin CAI ,  Tianzhu LI ,  Xiaoran KANG

IPC: A61F2/82 ,  A61L31/16 ,  A61L31/10 ,  A61L31/02 ,  A61L31/06 ,  A61L31/14

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipateldisappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

公开(公告)号：US20240245838A1

公开(公告)日：2024-07-25

申请号：US18424827

申请日：2024-01-28

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua SUN ,  Christophe BUREAU ,  Wenbin CAI ,  Tianzhu LI ,  Xiaoran KANG

IPC: A61L31/16 ,  A61F2/82 ,  A61K31/337 ,  A61K31/436 ,  A61L31/10 ,  A61L33/18 ,  B05D1/00 ,  B05D1/02 ,  B05D3/04

CPC classification number: A61L31/16 ,  A61F2/82 ,  A61K31/337 ,  A61K31/436 ,  A61L31/10 ,  A61L33/18 ,  B05D1/002 ,  B05D1/02 ,  B05D3/0486 ,  A61L2300/256 ,  A61L2300/258 ,  A61L2300/412 ,  A61L2300/416 ,  A61L2300/604 ,  A61L2420/08

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate, disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and or MACE.

公开(公告)号：US20250025607A1

公开(公告)日：2025-01-23

申请号：US18714809

申请日：2023-02-23

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY, INC.

Inventor： Christophe BUREAU ,  Ran SONG ,  Xiaomei ZHANG ,  Zhongcheng PAN ,  Hongtao FAN

IPC: A61L29/16 ,  A61L29/06

Abstract: A drug eluting balloon loaded with a drug in bulk, without any extra coating to host the said drug, and the method of preparing a drug eluting balloon which directly loads the drug on the balloon without coating, by using supercritical carbon dioxide to dissolve the drug and impregnate the balloons. The carbon dioxide is then released by pressure reduction, leaving only the drug on the balloon. Under suitable processing conditions, this method can form the drug uniformly on the surface of the balloon while maintaining the exterior morphology of the balloon, with a minimal increase in balloon thickness, and achieve satisfactory drug loading.

公开(公告)号：US20180042738A1

公开(公告)日：2018-02-15

申请号：US15797862

申请日：2017-10-30

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua SUN ,  Christophe BUREAU ,  Wenbin CAI ,  Tianzhu LI ,  Xiaoran KANG

IPC: A61F2/82 ,  A61L31/02 ,  A61L31/16 ,  A61L31/10

CPC classification number: A61F2/82 ,  A61F2250/0067 ,  A61L31/022 ,  A61L31/06 ,  A61L31/10 ,  A61L31/148 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/608 ,  A61L2420/02 ,  A61L2420/06 ,  C08L67/04

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.